Merck’s bad day: $310M for NotPetya, franchise drugs take a hit and now the EMA pushes back on Keytruda
Merck $MRK took a series of hits on Friday, capped by news after the market closed that its European application for its Keytruda/chemo combo for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
